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Background
This study aimed to survey the clinical spectrum of diffuse large B-cell lymphoma (DLBCL) 
in terms of epidemiology, pathologic subtypes, stage, and prognostic index as well as treat-
ment outcomes.
Methods
In 2007‒2008, 13 university hospitals evenly distributed in the Korean peninsula con-
tributed to the online registry of DLBCL at www.lymphoma.or.kr and filed a total of 1,665 
cases of DLBCL recorded since 1990.
Results
Our analysis showed a higher prevalence of DLBCL in male than in female individuals 
(M:F=958:707), and extranodal disease was more common than primary nodular disease 
(53% vs. 47%). Among the 1,544 patients who had been treated with CHOP 
(cyclophosphamide, doxorubicin, vincristine, and prednisone) or rituximab-CHOP 
(R-CHOP) therapy with or without radiation, 993 (63.9%) were alive, with 80% free of 
disease, 417 were dead (26.8%), with 13% free of disease, and 144 (9.3%) were lost to 
follow-up, with 23% free of disease. Age below 60 years, stage at diagnosis, international 
prognostic index (IPI) score regardless of age, and addition of rituximab to CHOP therapy 
in low- and low-intermediate-risk groups according to IPI scores significantly increased 
survival duration.
Conclusion
The epidemiology, clinical spectrum, and biological behavior of DLBCL in Korea are similar 
to those observed in Western countries, and the advent of rituximab improved survival.
Key Words Diffuse large B-cell lymphoma, Epidemiology, Survival, Rituximab, CHOP 
regimen
*This research was supported by Korean 
Society of Hematology Lymphoma 
Working Party.
Correspondence to
Chul Soo Kim, M.D., Ph.D. 
Department of Internal Medicine, Inha 
University College of Medicine, 27, 





Ⓒ 2013 Korean Society of Hematology
Blood Res 2013;48:115-20. bloodresearch.or.kr
116 Hyeon Gyu Yi, et al. 
INTRODUCTION
Diffuse large B-cell lymphoma (DLBCL) is the most com-
mon type of non-Hodgkin lymphoma (NHL) worldwide, 
accounting for 30% to 40% of all cases [1, 2]. In addition, 
in Korea, DLBCL is the most common disease representing 
42.6% of malignant lymphomas [3].
Since the anti-CD20 monoclonal antibody, rituximab, was 
added to the conventional standard chemotherapy CHOP 
(cyclophosphamide, doxorubicin, vincristine, and predni-
sone) regimen, the improvement in treatment outcomes of 
DLBCL has been proven by large-scale randomized trials 
and registry data [4-9]. Nonetheless, there have been few 
nationwide registry data regarding the clinical features of 
DLBCL in the era of rituximab in Korea or other Asian 
countries.
The Korean Lymphoma Working Party (KLWP) devel-
oped a nationwide web-based registry for DLBCL patients 
designated as the “Korean lymphoma Registry”, which in-
cludes data on age, pathologic subtypes, stage, prognostic 
index as well as treatment regimens, and therapeutic out-
comes for each patient. We retrospectively reviewed and 
analyzed the data of 1,665 Korean DLBCL patients.
MATERIALS AND METHODS
Patient registry
The registry committee of the KLWP designed the 
web-based DLBCL application for the Korean Lymphoma 
Registry (www.lymphoma.or.kr). The site was open from 
2007 through 2008, and 13 university hospitals evenly dis-
tributed in the Korean peninsula were involved. During this 
period, 1,665 cases of DLBCL encountered since 1990 were 
analyzed by 1 institution. The compiled variables included 
demographic features, clinical and laboratory disease charac-
teristics, chemotherapy regimens, treatment outcomes, and 
survival status. The collected clinical and laboratory data 
at diagnosis included the presence of extra-nodal involve-
ment, DLBCL subtype, complete blood cell counts, chemistry 
test results, and findings of bone marrow studies. Staging 
was determined in accordance with the Ann Arbor staging 
system, and risk groups were defined using the international 
prognostic index (IPI) and age-adjusted IPI (aaIPI) scoring 
system. Tumor response was evaluated using the Interna-
tional Working Group Criteria [10].
Statistics
Fisher’s exact test was applied to assess associations be-
tween categorical variables. Overall survival (OS) was meas-
ured from the date of diagnosis to the date of death or 
last follow-up and is reported in months. OS was estimated 
using the Kaplan-Meier method. The log-rank test was used 
to compare OS among groups. All statistical analyses were 
performed using a statistical software package (SPSS, Version 
17.0 Network version, Inc., Chicago, Ill., USA). Statistical 
analyses of categorical variables were performed using the 
chi-square test, and continuous data were compared using 
linear regression. Two-sided P values of ＜0.05 were consid-
ered statistically significant.
RESULTS
Characteristics and clinical features of patients
The demographic findings have been summarized at Table 
1. The median age at diagnosis was 58 years (range, 1‒95 
years). Of all patients analyzed, 958 (57.5%) were men and 
707 (42.5%) were women. Performance status according to 
the Eastern Cooperative Oncology Group scale was less than 
2 in 1,289 cases (83.0%). In terms of disease site, primary 
nodal DLBCL was detected in 458 people (46.9%), and ex-
tra-nodal DLBCL, in 519 (53.1%); the latter involved the 
stomach in 64 cases (12.3%), the gastrointestinal tract other 
than stomach in 57 (11.0%), the central nervous system 
in 73 (14.1%), and bone in 10 (1.9%). Rare types of DLBCL 
included mediastinal lymphoma (N=10), intravascular lym-
phoma (N=4), pyothorax-associated lymphoma (N=2), plas-
mablastic lymphoma (N=2), and primary effusion lymphoma 
(N=1). Further, 906 (54.3%) cases were classified as early 
stage (defined as Ann Arbor stages I, II), and 640 (38.3%), 
as advanced stage (Ann Arbor stages III, IV). B symptoms 
were present in 189 patients (32.0%), and tumor deposit 
in the bone marrow was found in 78 people (11.2%). 
Grouping according to the IPI score was as follows: 926 
(55.4%) patients had a score of 0/1; 438 (26.2%), a score 
of 2; 219 (13.1%), a score of 3; and 82 (5.0%), a score of 
4/5. The aaIPI score was 0 in 590 patients (35.4%), 1 in 
704 (42.2%), 2 in 312 (18.7%), 3 in 59 (3.5%). Hepatitis 
B surface antigen (HBs Ag) was positive in 113 cases (13.9%), 
anti-hepatitis C antibody (anti-HCV) was positive in 17 
(2.1%), and anti-human immunosuppressive antibody (anti- 
HIV) was positive in 3 (0.4%).
Treatment outcomes
Treatment including CHOP or rituximab-CHOP (R- 
CHOP) therapy with or without radiotherapy was carried 
out in 1,544 patients (92.7%), whereas no treatment was 
administered in 121 cases (7.3%) for various reasons. Among 
those who were treated, 499 (49.8%) received CHOP, and 
502 (50.2%), R-CHOP. After treatment, 499 (49.8%) received 
CHOP and 502 (50.2%) R-CHOP; 993 (63.9%) were alive 
in CR status [397 (79.9%)] or not [100 (21.1%)]; 417 (26.8%) 
died of relapse, 200(13.8%) of refractory disease, and 56 
(3.8%) of treatment-related causes; and 144 (9.3%) were 
lost to follow-up in CR status [21 (23%)] or not [69 (76.7%)]. 
Complete remission after first-line treatment was achieved 
in 928 patients (68.7%) (Table 2).
The median follow-up period was 17 months, and the 
1-year, 2-year and 5-year OS rates were 80.7%, 71.9%, and 
61.2%, respectively. OS was compared according to age (over 
60 vs. 60 years or less), IPI score, aaIPI score, and treatment 
regimen (CHOP vs. R-CHOP). OS was significantly shorter 
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Table 1. Characteristics of the DLBCL patients.
Gender 
    Male:female=958 (57.5%):707 (42.5%)
Diagnosis
    Primary nodal diffuse large B-cell lymphoma: 458 (46.9%)
    Primary extra-nodal diffuse large B-cell lymphoma: 519 (53.1%)
        Primary gastric lymphoma: 64 (12.3%)
        Primary gastrointestinal tract lymphoma (except stomach): 
57 (11.0%)
        Primary central nervous system lymphoma: 73 (14.1%)
        Primary bone lymphoma: 10 (1.9%)
    Mediastinal (thymic) large cell lymphoma: 10 
    Intravascular large B-cell lymphoma: 4 
    Primary effusion lymphoma: 1 
    Pyothorax-associated lymphoma: 2 
    Plasmablastic lymphoma: 2 
    Histologic transformation or combination with a low-grade 
component: 33 (Follicular lymphoma: 10)
Clinical manifestation
    Stage at diagnosis
        I: 405 (24.3%) 
        II: 501 (30.0%) 
        III: 261 (15.6%) 
        IV: 379 (22.7%) 
    B symptoms: 189 (32.0%) 
    Bone marrow involvement: 78 (11.2%)
    Performance status (Eastern Cooperative Oncology Group 
score)
        0‒1: 1,289 (83.0%)
        2: 153 (9.9%) 
        3: 92 (5.9%) 
        4: 19 (1.2%)
    International prognostic index (IPI) score 
        0/1: 373 (22.3%)/553 (33.1%) 
        2: 438 (26.2%) 
        3: 219 (13.1%) 
        4/5: 71 (4.3%)/11 (0.7%)
    Age-adjusted IPI (aaIPI) score 
        0: 590 (35.4%) 
        1: 704 (42.2%) 
        2: 312 (18.7%) 
        3: 59 (3.5%)
Disease involvement at diagnosis
    Nodal site
        Neck: 668 (38.9%)
        Waldeyer’s ring: 120 (7.0%)
    Extranodal site
        Stomach: 170 (18.1%) 
        Bone marrow: 86 (9.2%) 
        Central nervous system: 60 (6.4%) 
        Lung/Pleura: 65 (6.9%)/41 (4.4%) 
        Breast: 17 (1.8%) 
        Liver: 86 (9.2%) 
        Jejunum/Ileum: 8 (0.9%)/53 (5.7%) 
        Colon/Rectum: 55 (5.9%)/6 (0.6%) 
        Testis: 16 (1.7%) 
        Cerebrospinal fluid: 13 (1.4%) 
        Bone: 72 (7.7%)
Table 2. Treatment outcomes of DLBCL patients.
Treatment outcomes
    Alive: 993 (63.9%)
        Complete remission (CR) 397 (79.9%)/non-CR 100 (20.1%)
    Dead: 417 (26.8%)
        CR 21 (13.1%)/non-CR 139 (86.9%)
        Death related to relapse or progression: 200 (13.8%)
        Death related to treatment-related toxicity (except 
transplantation): 49 (3.4%)
        Death with transplantation-related cause: 3 (0.2%)
        Death related to secondary malignancy: 4 (0.3%)
    Lost to follow-up: 144 (9.3%) 
        CR 21 (23.3%)/non-CR 69 (76.7%)
    First CR achievement: 928 (68.7%)
    First relapse: 361 (24.4%)
in patients over 60 years (N=933, 55.9%) than in patients 
aged 60 years or less (N=736, 44.1%; P＜0.001). The overall 
trend of superior OS for R-CHOP compared to CHOP was 
not significant (P=0.059). On stratification according to each 
risk group, OS was significantly longer for R-CHOP than 
for CHOP in low- and low-intermediate-risk groups (P= 
0.005, P=0.029, respectively), but not in the high-inter-
mediate- and high-risk groups (Fig. 1). The IPI score and 
aaIPI score had a statistically meaningful impact on survival 
duration (P＜0.001), regardless of the treatment modality 
(Figs. 2 and 3).
DISCUSSION
This web-based registry study, which involved 13 hospitals 
distributed evenly in the Korean peninsula, included the 
largest number of DLBCL patients among the studies reported 
in Korea so far and represents the best estimate of the clinical 
characteristics and outcomes of DLBCL.
We used anti-nuclear antibody (ANA), HBs Ag, anti-HCV, 
and anti-HIV to investigate if there was any relationship 
between viral infection and the incidence of DLBCL, as 
previously reported [11-13]. Of note, we found that the 
prevalence of HBs Ag positivity was much higher among 
DLBCL patients than in the general population of Korea 
surveyed by the national cancer screening program (13.9% 
vs. 2.57%), suggesting a possible impact of hepatitis B virus 
infection on the development of DLBCL [12, 14].
The proportion of patients with extra-nodal involvement 
of DLBCL in this study (58.1%) was similar to that reported 
by Yang at al. in China (60.1%), which is higher than that 
in Western countries (30‒40%) [15-17]. Higher prevalence 
of Helicobacter pylori infection in Asian countries might 
in part contribute to this phenomenon. Further epidemio-
logical studies are required to confirm these results.
The benefit of rituximab on survival in DLBCL patients 
has been proved by several studies [4-9]. However, in our 
study, the improvement of OS in the R-CHOP group com-
pared with the CHOP group was not confirmed. Moreover, 
the difference in OS between each treatment group was 
only observed in the low- and low-intermediate-risk groups 
(Fig. 1). This discrepancy between our study and other studies 
can be explained by the limitations of retrospective studies, 
such as unmatched number of the patients between treatment 
groups and short follow-up duration of R-CHOP patients 
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Fig. 1. Comparison of OS in patients treated with CHOP vs. R-CHOP stratified according to risk: low-risk group (A), low-intermediate-risk group 
(B), high-intermediate-risk group (C), and high-risk group (D).
Fig. 2. OS according to IPI (A) and aaIPI (B) scores for all patients. The log-rank P value for both indices was ＜0.001.
bloodresearch.or.kr Blood Res 2013;48:115-20.
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Fig. 3. Predictive power of the IPI (A, B) and aaIPI (C, D) scoring systems for each treatment group. The log-rank P value for both indices was ＜0.001. 
Discrimination between the high-intermediate- and high-risk groups seemed to be difficult among patients treated with CHOP.
compared to CHOP patients. Furthermore, the survival bene-
fit of rituximab might diminish over time because of the 
increase in non-lymphoma deaths, as suggested by the 
long-term results of GELA [9].
The optimal prognostic indices of DLBCL patients have 
been debated particularly since the introduction of rituxi-
mab. Some reports suggested that the revised IPI scoring 
system was more suitable than the IPI scoring system in 
patients treated with R-CHOP [18]. In our study, both IPI 
and aaIPI scoring systems effectively predicted OS in all 
patients group (Fig. 2). Among the patients treated with 
R-CHOP, both IPI and aaIPI scores were effective prognostic 
factors consistent with the result of the study from the 
Lunenburg Lymphoma Biomarker Consortium, which in-
dicated that these 2 parameters were good prognostic indices 
for rituximab treatment (Fig. 3B, 3D) [19, 20]. However, 
neither IPI scores nor aaIPI scores could discriminate be-
tween the high-intermediate- and high-risk groups among 
CHOP-treated patients (Fig. 3A, 3C).
In conclusion, we presented the latest analysis of the epi-
demiological and clinical characteristics and clinical out-
comes of patients with DLBCL in Korea, based on a nation-
wide web-based registry enlisting the largest number of 
DLBCL patients reported so far.
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